| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $442,754,263 | 34 | 100 |
| Albers Jeffrey W. | director | 0 | $0 | 1 | $2.4M | $-2.4M |
| King-Jones Heidy | See Remarks | 0 | $0 | 3 | $5.11M | $-5.11M |
| Sloan Sheldon | Chief Medical Officer | 0 | $0 | 4 | $7.35M | $-7.35M |
| HENDERSON MICHAEL THOMAS | director | 0 | $0 | 2 | $7.95M | $-7.95M |
| Burrows Scott L | Chief Financial Officer | 0 | $0 | 11 | $9.12M | $-9.12M |
| Turtle Cameron | Chief Executive Officer | 0 | $0 | 13 | $12.2M | $-12.2M |
| Fairmount Funds Management LLC | director | 0 | $0 | 1 | $399.66M | $-399.66M |
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal …
Over the last 12 months, insiders at Spyre Therapeutics, Inc. have bought $0 and sold $442.75M worth of Spyre Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Spyre Therapeutics, Inc. have bought $0 and sold $148.29M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-10-01 | Sale | Turtle Cameron | Chief Executive Officer | 15,000 0.0177% | $92.01 | $1.38M | +1.63% | |
| 2026-10-01 | Sale | Burrows Scott L | Chief Financial Officer | 7,500 0.0088% | $91.83 | $688,756 | +1.63% | |
| 2026-10-01 | Sale | King-Jones Heidy | See Remarks | 28,933 0.0337% | $91.03 | $2.63M | +1.63% | |
| 2026-09-30 | Sale | Burrows Scott L | Chief Financial Officer | 17,500 0.0203% | $89.89 | $1.57M | +2.06% | |
| 2026-09-02 | Sale | Burrows Scott L | Chief Financial Officer | 18,232 0.0215% | $89.35 | $1.63M | +3.68% | |
| 2026-09-02 | Sale | King-Jones Heidy | See Remarks | 400 0.0005% | $90.00 | $36,000 | +3.68% | |
| 2026-09-01 | Sale | Turtle Cameron | Chief Executive Officer | 15,000 0.017% | $87.29 | $1.31M | +1.80% | |
| 2026-09-01 | Sale | Burrows Scott L | Chief Financial Officer | 7,500 0.0085% | $87.31 | $654,792 | +1.80% | |
| 2026-09-01 | Sale | King-Jones Heidy | See Remarks | 27,999 0.0318% | $87.31 | $2.44M | +1.80% | |
| 2026-08-07 | Sale | Albers Jeffrey W. | director | 23,000 0.027% | $104.53 | $2.4M | -13.31% | |
| 2026-08-03 | Sale | Turtle Cameron | Chief Executive Officer | 15,000 0.0044% | $95.51 | $1.43M | -3.72% | |
| 2026-08-03 | Sale | Burrows Scott L | Chief Financial Officer | 7,500 0.0022% | $95.57 | $716,771 | -3.72% | |
| 2026-07-01 | Sale | Turtle Cameron | Chief Executive Officer | 15,000 0.0245% | $87.69 | $1.32M | +5.31% | |
| 2026-07-01 | Sale | Burrows Scott L | Chief Financial Officer | 7,500 0.0123% | $87.74 | $658,040 | +5.31% | |
| 2026-07-01 | Sale | Sloan Sheldon | Chief Medical Officer | 8,334 0.0136% | $87.70 | $730,896 | +5.31% | |
| 2026-06-25 | Sale | Burrows Scott L | Chief Financial Officer | 15,000 0.0244% | $87.13 | $1.31M | +4.83% | |
| 2026-06-23 | Sale | Fairmount Funds Management LLC | director | 4.68M 6.5956% | $85.31 | $399.66M | -4.27% | |
| 2026-06-22 | Sale | HENDERSON MICHAEL THOMAS | director | 20,000 0.033% | $100.00 | $2M | -7.37% | |
| 2026-06-03 | Sale | Sloan Sheldon | Chief Medical Officer | 8,333 0.015% | $75.00 | $624,975 | +25.14% | |
| 2026-06-01 | Sale | Turtle Cameron | Chief Executive Officer | 11,706 0.0193% | $70.17 | $821,360 | +29.98% |
| Increased Positions | 106 | +100.95% | 23M | +35.42% |
| Decreased Positions | 42 | -40% | 6M | -9.49% |
| New Positions | 31 | New | 5M | New |
| Sold Out Positions | 15 | Sold Out | 2M | Sold Out |
| Total Postitions | 169 | +60.95% | 81M | +25.93% |
| Fmr Llc | $277,059.00 | 11.62% | 9.06M | +7,110 | +0.08% | 2025-09-30 |
| Fairmount Funds Management Llc | $122,874.00 | 5.15% | 4.02M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $121,792.00 | 5.11% | 3.98M | -24,552 | -0.61% | 2025-09-30 |
| Rtw Investments, Lp | $110,761.00 | 4.64% | 3.62M | 0 | 0% | 2025-09-30 |
| Tang Capital Management Llc | $97,856.00 | 4.1% | 3.2M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $93,291.00 | 3.91% | 3.05M | -15,856 | -0.52% | 2025-09-30 |
| Vr Adviser, Llc | $82,121.00 | 3.44% | 2.69M | 0 | 0% | 2025-09-30 |
| Braidwell Lp | $78,848.00 | 3.31% | 2.58M | 0 | 0% | 2025-09-30 |
| Capital International Investors | $73,164.00 | 3.07% | 2.39M | 0 | 0% | 2025-09-30 |
| Driehaus Capital Management Llc | $63,006.00 | 2.64% | 2.06M | -25,215 | -1.21% | 2025-09-30 |